Medtronic plc. (MDT)
MDT trades on NYSE in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-04-24, https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/0001628280-26-044354-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-04-24.
Profile
| Field | Value |
|---|---|
| Ticker | MDT on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001613103 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $36.4B |
| Net income | $4.8B |
| Operating income | $6.5B |
| Net margin | 13.2% |
| Operating margin | 17.8% |
| Revenue growth | +8.4% |
| Cash | $1.9B |
| Total assets | $93.0B |
| P/E (computed) | 27.4× |
| P/S (computed) | 3.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-09-03 |
| Cash and burn | $1.7B cash; operating cash flow $2.0B a quarter. | Report 2026-07-31 |
| Shares outstanding | 1,279,137,890 (2026-08-28); 1,282,685,882 a year earlier; 1,330,533,713 three years earlier. | Cover page 2026-08-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-10-15 |
| Auditor | PricewaterhouseCoopers LLP, Minneapolis, Minnesota, United States | PCAOB Form AP 2026-07-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $8.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-07-31 | $9.8B | $1.5B | $1.8B | $1.7B | $28.2B | $37.5B | 10-Q 2026-09-03 |
| Q4 2026 2026-04-24 | $9.8B | $1.2B | $2.6B | $1.9B | $28.0B | $36.4B | 10-K 2026-06-18 |
| Q3 2026 2026-01-23 | $9.0B | $1.1B | $2.7B | $1.1B | $28.1B | $35.5B | 10-Q 2026-02-24 |
| Q2 2026 2025-10-24 | $9.0B | $1.4B | $925.0M | $1.3B | $29.1B | $34.8B | 10-Q 2025-11-25 |
| Q1 2026 2025-07-25 | $8.6B | $1.0B | $1.1B | $1.3B | $28.6B | $34.2B | 10-Q 2026-09-03 |
| Q4 2025 2025-04-25 | $8.9B | $1.1B | $2.5B | $2.2B | $28.5B | $33.5B | 10-K 2026-06-18 |
| Q3 2025 2025-01-24 | $8.3B | $1.3B | $2.6B | $1.2B | $26.6B | $33.2B | 10-Q 2026-02-24 |
| Q2 2025 2024-10-25 | $8.4B | $1.3B | $958.0M | $1.4B | $28.3B | $33.0B | 10-Q 2025-11-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-03-09 |
| Latest annual report | 10-K | 2026-06-18 |
| Latest quarterly / interim | 10-Q | 2026-09-03 |
| Latest current report | 8-K | 2026-10-19 |
| Latest proxy | DEFA14A | 2026-08-17 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.0% |
| 1 month | +10.6% |
| 3 months | +13.6% |
| Year to date | +7.1% |
| 1 year | +7.0% |
| From 52-week high | -2.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LIVN | LivaNova PLC | $92.44 | +1.23% | $5.1B |
| AXGN | Axogen Inc. | $55.38 | -0.98% | $3.3B |
| TMDX | TransMedics Group Inc. | $92.21 | +0.91% | $3.2B |
| CNMD | CONMED Corporation | $49.35 | -2.45% | $1.5B |
| CBLL | CeriBell Inc. | $26.42 | +1.07% | $1.0B |
| INMD | InMode Ltd. | $13.15 | -0.90% | $755.9M |
| CV | CapsoVision Inc. | $6.47 | +7.30% | $346.9M |
| ELMD | Electromed Inc. | $23.10 | -5.02% | $188.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier